These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
235 related items for PubMed ID: 31564053
1. From Patients to Platelets and Back Again: Pharmacological Approaches to Glycoprotein VI, a Thrilling Antithrombotic Target with Minor Bleeding Risks. Martins Lima A, Martins Cavaco AC, Fraga-Silva RA, Eble JA, Stergiopulos N. Thromb Haemost; 2019 Nov; 119(11):1720-1739. PubMed ID: 31564053 [Abstract] [Full Text] [Related]
2. Trowaglerix Venom Polypeptides As a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet. Chang CH, Chung CH, Tu YS, Tsai CC, Hsu CC, Peng HC, Tseng YJ, Huang TF. Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1307-1314. PubMed ID: 28596377 [Abstract] [Full Text] [Related]
3. GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease. Slater A, Khattak S, Thomas MR. Eur Heart J Cardiovasc Pharmacother; 2024 Aug 14; 10(5):465-473. PubMed ID: 38453424 [Abstract] [Full Text] [Related]
5. Current and future antiplatelet therapies: emphasis on preserving haemostasis. McFadyen JD, Schaff M, Peter K. Nat Rev Cardiol; 2018 Mar 14; 15(3):181-191. PubMed ID: 29297508 [Abstract] [Full Text] [Related]
7. Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke. Induruwa I, Jung SM, Warburton EA. Int J Stroke; 2016 Aug 14; 11(6):618-25. PubMed ID: 27312676 [Abstract] [Full Text] [Related]
9. [Advances of Studies on Platelet GPVI as Antithrombotic Target -Review]. Li P, Qiao JL, Xu KL. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb 14; 25(1):264-269. PubMed ID: 28245414 [Abstract] [Full Text] [Related]
10. Platelet GPVI (Glycoprotein VI) and Thrombotic Complications in the Venous System. Perrella G, Nagy M, Watson SP, Heemskerk JWM. Arterioscler Thromb Vasc Biol; 2021 Nov 14; 41(11):2681-2692. PubMed ID: 34496636 [Abstract] [Full Text] [Related]
13. Modulation of Glycoprotein VI and Its Downstream Signaling Pathways as an Antiplatelet Target. Fuentes E. Int J Mol Sci; 2022 Aug 31; 23(17):. PubMed ID: 36077280 [Abstract] [Full Text] [Related]
14. GSK669, a NOD2 receptor antagonist, inhibits thrombosis and oxidative stress via targeting platelet GPVI. Pan G, Chang L, Zhang J, Liu Y, Hu L, Zhang S, Zhang J, Qiao J, Jakopin Ž, Hu H, Dong J, Ding Z. Biochem Pharmacol; 2021 Jan 31; 183():114315. PubMed ID: 33152345 [Abstract] [Full Text] [Related]
15. Future Antithrombotic Therapies in Cardiology. Bäuml M, Hilgendorf I. Hamostaseologie; 2018 Nov 31; 38(4):236-239. PubMed ID: 30267387 [Abstract] [Full Text] [Related]
16. Platelets and primary haemostasis. Clemetson KJ. Thromb Res; 2012 Mar 31; 129(3):220-4. PubMed ID: 22178577 [Abstract] [Full Text] [Related]
18. New advances in treating thrombotic diseases: GPVI as a platelet drug target. Jiang P, Jandrot-Perrus M. Drug Discov Today; 2014 Sep 31; 19(9):1471-5. PubMed ID: 24931218 [Abstract] [Full Text] [Related]
19. Platelet GPVI: a target for antithrombotic therapy?! Dütting S, Bender M, Nieswandt B. Trends Pharmacol Sci; 2012 Nov 31; 33(11):583-90. PubMed ID: 22901552 [Abstract] [Full Text] [Related]
20. Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'. Kraft P, De Meyer SF, Kleinschnitz C. J Cereb Blood Flow Metab; 2012 Oct 31; 32(10):1831-40. PubMed ID: 22805877 [Abstract] [Full Text] [Related] Page: [Next] [New Search]